Recent Progress in Structures and Functions of Hepatitis C Virus NS3/4A Proteins
Open Access
Abstract
Hepatitis C virus (HCV) chronically infects over 50 million people worldwide and poses a significant risk to global health. The HCV NS3/4A complex, a bifunctional enzyme comprising a protease and a helicase domain, is indispensable for viral replication and immune evasion, making it a pivotal target for direct-acting antiviral agents (DAAs). Here, we summarize its structural features, functional mechanisms, and implications in drug design and protein engineering (e.g., nanopore sequencing applications). The NS3 protease domain is activated by the NS4A cofactor, which mediates viral polyprotein processing and relies on a zinc-binding site for structural stability. The C-terminal helicase domain catalyzes ATP-dependent 3′→5′ unwinding, and allosteric crosstalk between the protease and helicase domains dynamically modulates the enzymatic activity, balancing unwinding velocity and processivity. Beyond supporting viral replication, NS3/4A cleaves MAVS to abolish RIG-I/MDA5 signaling but spares TRIF, leaving TLR3-mediated immunity intact; it also modulates host lipid and iron metabolism, contributing to HCV pathogenesis. Notably, structural and functional studies of NS3/4A lay a solid theoretical foundation for developing novel therapeutic strategies. Currently, DAAs targeting NS3/4A have achieved high sustained virologic response rates; however, resistance-associated substitutions remain a major clinical challenge, particularly in genotype 3 infections. Emerging therapeutic strategies targeting NS3/4A include allosteric inhibition and proteolysis-targeting chimeras (PROTACs)-mediated degradation.Keywords
Funding Information
- National Key Research and Development Program of China (2023YFF1206001)
- National Natural Science Foundation of China (32371268)
This publication has 64 references indexed in Scilit:
- Nanopore‐Based Label‐Free and Single‐Molecule Sequencing toward Precision DiagnosisAdvanced Materials, 2025
- On the steroids extracted from soft corals against the NS3/4A protease of hepatitis C virusJournal of Molecular Graphics and Modelling, 2024
- Unraveling the mechanisms of Sofosbuvir resistance in HCV NS3/4A protease: Structural and molecular simulation-based insightsInternational Journal of Biological Macromolecules, 2024
- Polymorphic Structure Determination of the Macrocyclic Drug Paritaprevir by MicroEDAdvanced Biology, 2024
- Mechanisms and Clinical Significance of Pharmacokinetic Drug Interactions Mediated by FDA and EMA-approved Hepatitis C Direct-Acting Antiviral AgentsClinical Pharmacokinetics, 2023
- Comparison of HAV and HCV infections in vivo and in vitro reveals distinct patterns of innate immune evasion and activationJournal of Hepatology, 2023
- Deciphering the Molecular Mechanism of HCV Protease Inhibitor Fluorination as a General Approach to Avoid Drug ResistanceJournal of Molecular Biology, 2022
- HCV: The Journey from Discovery to a Cure2019
- The interdomain interface in bifunctional enzyme protein 3/4A (NS3/4A) regulates protease and helicase activitiesProtein Science, 2013
- Induced‐Fit Binding of the Macrocyclic Noncovalent Inhibitor TMC435 to its HCV NS3/NS4A Protease TargetAngewandte Chemie International Edition, 2010